Innovent Biologics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IVBXF research report →
Price Chart
About the company
Innovent Biologics, Inc. , established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing.
- CEO
- De-Chao Yu
- IPO
- 2019
- Employees
- 7,502
- HQ
- Suzhou, JS, CN
Get TickerSpark's AI analysis on IVBXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $19.05B
- P/E
- 100.31
- Fwd P/E
- 7.76
- PEG
- 16.80
- P/S
- 7.94
- P/B
- 5.91
- EV/EBITDA
- 42.81
- Div Yield
- 0.00%
- Gross Margin
- 80.96%
- Op Margin
- 12.02%
- Net Margin
- 7.80%
- ROE
- 6.06%
- ROIC
- 4.53%
Latest fiscal year · YoY change
- Revenue
- $12.70B+34.8%
- Gross Profit
- $10.99B+39.0%
- Op Income
- $1.97B
- Net Income
- $792.57M+937.5%
- EPS
- $0.47+909.0%
- OCF Growth
- +677.1%
- FCF Growth
- +2327.1%
- 52W High
- $15.01
- 52W Low
- $9.10
- 50D MA
- $11.72
- 200D MA
- $11.28
- Beta
- 0.24
- RSI (14)
- 46
- Avg Volume
- 2.00K
No earnings-call transcripts are available for IVBXF yet.
- Free Float
- 92.6%
- Shares Outstanding
- 1.74B
- Float Shares
- 1.61B
Held by 3 ETFs
Biggest fund positions in IVBXF by dollar value.
Our IVBXF coverage
Recent articles, reports, and earnings notes.
No research on IVBXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IVBXF report →Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hyperlipidemia Demonstrated Potent Lipid-lowering Efficacy
prnewswire.com · Nov 8
Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China
benzinga.com · Jul 1
China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug
reuters.com · Jun 30
Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review
reuters.com · Jun 29
Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026
prnewswire.com · Jun 24
Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
prnewswire.com · Jun 21
Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
cnbc.com · May 28
China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal
reuters.com · May 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.